ATE383849T1 - Transdermale pharmazeutische zusammensetzung - Google Patents

Transdermale pharmazeutische zusammensetzung

Info

Publication number: ATE383849T1
Authority: AT; Austria
Prior art keywords: transdermal; pharmaceutical composition; transdermal pharmaceutical; trioleate; glyceryl
Prior art date: 2003-10-09

Application number

AT04769091T

Other languages

English (en)

Inventor

Istvan Eros

Csoka Ildiko Pannonhalmine

Csanyi Erzsebet Soosn

Attila Bodis

Erzsebet Lapis

Czinege Erzsebet Francsicsne

Csikos Emoke Kissne

Janos Illes

Original Assignee

Richter Gedeon Vegyeszet

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-10-09

Filing date

2004-10-06

Publication date

2008-02-15

2004-10-06 Application filed by Richter Gedeon Vegyeszet filed Critical Richter Gedeon Vegyeszet

2008-02-15 Application granted granted Critical

2008-02-15 Publication of ATE383849T1 publication Critical patent/ATE383849T1/de

Links

239000008194 pharmaceutical composition Substances 0.000 title abstract 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract 6
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical class CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 abstract 2
HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 abstract 2
229940074928 isopropyl myristate Drugs 0.000 abstract 2
239000004973 liquid crystal related substance Substances 0.000 abstract 2
229960004063 propylene glycol Drugs 0.000 abstract 2
235000013772 propylene glycol Nutrition 0.000 abstract 2
229940117972 triolein Drugs 0.000 abstract 2
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 abstract 1
239000002537 cosmetic Substances 0.000 abstract 1
229940011871 estrogen Drugs 0.000 abstract 1
239000000262 estrogen Substances 0.000 abstract 1
230000035876 healing Effects 0.000 abstract 1
238000002657 hormone replacement therapy Methods 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
239000000583 progesterone congener Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Physical Education & Sports Medicine (AREA)
Endocrinology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Psychiatry (AREA)
Reproductive Health (AREA)
Diabetes (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Hospice & Palliative Care (AREA)
Dispersion Chemistry (AREA)
Urology & Nephrology (AREA)
Anesthesiology (AREA)
Gynecology & Obstetrics (AREA)
Otolaryngology (AREA)
Vascular Medicine (AREA)
Tropical Medicine & Parasitology (AREA)

AT04769091T 2003-10-09 2004-10-06 Transdermale pharmazeutische zusammensetzung ATE383849T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
HU0303313A HUP0303313A2 (hu)	2003-10-09	2003-10-09	Transzdermális gyógyszerkészítmények

Publications (1)

Publication Number	Publication Date
ATE383849T1 true ATE383849T1 (de)	2008-02-15

Family

ID=90001702

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04769091T ATE383849T1 (de)	2003-10-09	2004-10-06	Transdermale pharmazeutische zusammensetzung

Country Status (13)

Country	Link
US (1)	US7728042B2 (de)
EP (1)	EP1673063B1 (de)
JP (1)	JP4884223B2 (de)
AT (1)	ATE383849T1 (de)
DE (1)	DE602004011374T2 (de)
DK (1)	DK1673063T3 (de)
EA (1)	EA009900B1 (de)
ES (1)	ES2300820T3 (de)
HU (1)	HUP0303313A2 (de)
NO (1)	NO20062053L (de)
PL (1)	PL1673063T3 (de)
RS (2)	RS51764B (de)
WO (1)	WO2005032514A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050238672A1 (en) *	2004-04-27	2005-10-27	Nimni Marcel E	Antifungal drug delivery
WO2006118246A1 (ja) *	2005-04-28	2006-11-09	Japan Science And Technology Agency	経皮吸収促進剤
FR2900575B1 (fr) *	2006-05-05	2008-10-17	Anteis Sa	Gel biocompatible a liberation controlee, son procede de preparation et son utilisation
HUP0700828A2 (en) *	2007-12-20	2010-01-28	Richter Gedeon Nyrt	Transdermal pharmaceutical compositions containing tolperisone alone and in combination
ES2326721B1 (es) *	2008-01-04	2010-07-16	Endor Nanotechnologies, S.L.	Conjugado de acido hialuronico para el tratamiento cosmetico y procedimiento de preparacion.
WO2010069519A1 (en) *	2008-12-18	2010-06-24	Merz Pharma Gmbh & Co. Kgaa	Topical compositions comprising at least one active ingredient poorly soluble in water and biopolymers such as hyaluronic acid with a pka-value between 5-7
US20110033515A1 (en) *	2009-08-04	2011-02-10	Rst Implanted Cell Technology	Tissue contacting material
WO2011109367A2 (en) *	2010-03-02	2011-09-09	Royster Jr George E	Methods and compositions for treating or preventing symptoms of hormonal variations
US8461102B2 (en)	2010-03-02	2013-06-11	George E. Royster, JR.	Methods and compositions for treating and preventing symptoms of hormonal variations
AU2011292044A1 (en)	2010-08-18	2013-04-04	Del Mar Pharmaceuticals	Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dianhydrogalactitol and diacetyldianhydrogalactitol
US9114258B2 (en) *	2011-01-04	2015-08-25	Kato Medical Systems Llc	Electrokinetic nerve stimulator
EP3795145A3 (de)	2011-08-17	2021-06-09	Dennis M. Brown	Zusammensetzungen und verfahren zur erhöhung des therapeutischen nutzens von suboptimal verabreichten chemischen verbindungen einschliesslich substituierter hexitole wie dibromodulcitol
US9301920B2 (en)	2012-06-18	2016-04-05	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
US8633178B2 (en)	2011-11-23	2014-01-21	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
EP2804602B1 (de)	2012-01-20	2024-12-04	Del Mar Pharmaceuticals	Verwendung von substituierten hexitolen mit dianhydrogalactitol und analoga zur behandlung von neoplastischen erkrankungen und krebsstammzellen einschliesslich glioblastoma multforme und medulloblastoma
WO2013169600A1 (en)	2012-05-09	2013-11-14	Delmar Pharmaceuticals	Veterinary use of dianhydrogalactitol, diacetyldianhydrogalactitol, and dibromodulcitol to treat malignancies
US10806697B2 (en)	2012-12-21	2020-10-20	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en)	2012-06-18	2020-10-20	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
US20130338122A1 (en)	2012-06-18	2013-12-19	Therapeuticsmd, Inc.	Transdermal hormone replacement therapies
US20150196640A1 (en)	2012-06-18	2015-07-16	Therapeuticsmd, Inc.	Progesterone formulations having a desirable pk profile
JP6280546B2 (ja)	2012-06-26	2018-02-14	デルマーファーマシューティカルズ	ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
CA2882870C (en) *	2012-08-24	2020-12-15	Integurx Therapeutics, Llc	Chemical compositions and methods for enhancing transdermal delivery of therapeutic agents
US10537581B2 (en)	2012-12-21	2020-01-21	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en)	2012-12-21	2022-03-08	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en)	2012-12-21	2019-11-12	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en)	2012-12-21	2022-02-15	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en)	2012-12-21	2020-02-25	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en)	2012-12-21	2015-11-10	Therapeuticsmd, Inc.	Soluble estradiol capsule for vaginal insertion
HU230989B1 (hu) *	2013-01-17	2019-08-28	Gd Photonics Kft.	Készítmény az UVB-fényterápia hatékonyságának fokozására, eljárás annak előállítására és alkalmazása
KR20160061911A (ko)	2013-04-08	2016-06-01	데니스 엠. 브라운	최적하 투여된 화학 화합물의 치료 효과
JP6125547B2 (ja) *	2013-04-24	2017-05-10	あすか製薬株式会社	無定形レボノルゲストレル、固体分散体及びそれらの製造方法
CN112472699A (zh)	2013-07-26	2021-03-12	种族肿瘤学公司	改善比生群及衍生物的治疗益处的组合方法
SG11201608303QA (en)	2014-04-04	2016-11-29	Del Mar Pharmaceuticals	Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
EP3145489A1 (de)	2014-05-22	2017-03-29	TherapeuticsMD, Inc.	Natürliche kombinierte hormonersatzformulierungen und therapien
RU2016141135A (ru)	2014-07-29	2018-08-28	Терапьютиксмд, Инк.	Трансдермальный крем
CN104725370B (zh) *	2015-03-19	2017-03-01	天津大学	一种长春西汀管状晶体及制备方法
US10328087B2 (en)	2015-07-23	2019-06-25	Therapeuticsmd, Inc.	Formulations for solubilizing hormones
WO2017173044A1 (en)	2016-04-01	2017-10-05	Therapeuticsmd Inc.	Steroid hormone compositions in medium chain oils
WO2017173071A1 (en)	2016-04-01	2017-10-05	Therapeuticsmd, Inc.	Steroid hormone pharmaceutical composition
CN109091451B (zh) *	2018-09-10	2021-08-13	武汉百纳礼康生物制药有限公司	亲水性药物的油相液晶凝胶前体制剂及其制备方法
RU2712918C1 (ru) *	2019-08-01	2020-02-03	Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации	Способ предотвращения острой боли при выполнении химического плевродеза после радикальных торакопластических операций онкологического характера
CN112426403B (zh) *	2020-12-09	2021-09-17	南京天纵易康生物科技股份有限公司	一种口腔溃疡凝胶及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4968539A (en) *	1987-12-01	1990-11-06	Lion Corporation	Liquid crystal membrane
US6458774B1 (en) *	1989-02-24	2002-10-01	Richter Gedeon Vegyeszeti Gyar Rt.	Compositions containing hyaluronic acid associates and a process for preparing same
CA1340994C (en) *	1989-09-21	2000-05-16	Rudolf Edgar Dr. Falk	Treatment of conditions and disease
IT1248666B (it) *	1990-05-30	1995-01-26	Fidia Spa	Gel in forma di film autosupportanti altamente idrati, processo per laloro preparazione e impiego nella terapia di lesioni e/o patologie cutanee
HU209605B (en) *	1991-04-15	1994-09-28	Chinoin Gyogyszer Es Vegyeszet	Process for production of wather-free transdermal preparation
US5326566A (en) *	1991-05-17	1994-07-05	Bristol-Myers Squibb Company	Use of dibutyl adipate and isopropyl myristate in topical and transdermal products
TW218849B (de) *	1991-05-17	1994-01-11	Bristol Myers Squibb Co
US5616568A (en) *	1993-11-30	1997-04-01	The Research Foundation Of State University Of New York	Functionalized derivatives of hyaluronic acid
ES2331302T3 (es) *	2001-05-01	2009-12-29	A.V. Topchiev Institute Of Petrochemical Synthesis	Composiciones de hidrogel.
ES2337129T3 (es) *	2001-05-23	2010-04-21	Pantarhei Bioscience B.V.	Sistema de administracion de medicamento comprendiendo un estrogeno tetrahidroxilado para el uso en la anticoncepcion hormonal.
JP2003063996A (ja) *	2001-08-23	2003-03-05	禎秀 ▲廣▼▲崎▼	皮膚外用剤
US6960563B2 (en) *	2001-08-31	2005-11-01	Morton Grove Pharmaceuticals, Inc.	Spontaneous emulsions containing cyclosporine

2003
- 2003-10-09 HU HU0303313A patent/HUP0303313A2/hu unknown
2004
- 2004-10-06 RS RS20060249A patent/RS51764B/sr unknown
- 2004-10-06 RS YUP-2006/0249A patent/RS20060249A/sr unknown
- 2004-10-06 US US10/575,145 patent/US7728042B2/en not_active Expired - Fee Related
- 2004-10-06 JP JP2006530614A patent/JP4884223B2/ja not_active Expired - Fee Related
- 2004-10-06 WO PCT/HU2004/000092 patent/WO2005032514A1/en not_active Ceased
- 2004-10-06 DE DE602004011374T patent/DE602004011374T2/de not_active Expired - Lifetime
- 2004-10-06 PL PL04769091T patent/PL1673063T3/pl unknown
- 2004-10-06 ES ES04769091T patent/ES2300820T3/es not_active Expired - Lifetime
- 2004-10-06 AT AT04769091T patent/ATE383849T1/de active
- 2004-10-06 EP EP04769091A patent/EP1673063B1/de not_active Expired - Lifetime
- 2004-10-06 DK DK04769091T patent/DK1673063T3/da active
- 2004-10-06 EA EA200600750A patent/EA009900B1/ru not_active IP Right Cessation
2006
- 2006-05-08 NO NO20062053A patent/NO20062053L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
PL1673063T3 (pl)	2008-06-30
ES2300820T3 (es)	2008-06-16
NO20062053L (no)	2006-05-08
US7728042B2 (en)	2010-06-01
EA009900B1 (ru)	2008-04-28
RS20060249A (sr)	2008-06-05
HUP0303313A2 (hu)	2005-07-28
RS51764B (sr)	2011-12-31
JP2007508287A (ja)	2007-04-05
EA200600750A1 (ru)	2006-08-25
DK1673063T3 (da)	2008-05-19
EP1673063A1 (de)	2006-06-28
HUP0303313D0 (en)	2003-12-29
EP1673063B1 (de)	2008-01-16
US20070264345A1 (en)	2007-11-15
JP4884223B2 (ja)	2012-02-29
DE602004011374T2 (de)	2009-01-08
DE602004011374D1 (de)	2008-03-06
WO2005032514A1 (en)	2005-04-14

Legal Events

Date

Code

Title

Description

2008-09-15

UEP

Publication of translation of european patent specification

Ref document number: 1673063

Country of ref document: EP

Publication	Publication Date	Title
ATE383849T1 (de)	2008-02-15	Transdermale pharmazeutische zusammensetzung
IL154888A (en)	2013-12-31	Aqueous Pharmaceutical Gel Preparation Containing At least One Vitamin D or One Vitamin D Analog At least One Corticosteroid
BR0108173A (pt)	2003-01-21	Composições farmacêuticas de toxina de botulina
EA200801492A1 (ru)	2008-10-30	Фармацевтическое применение замещенных амидов
SG151329A1 (en)	2009-04-30	Amido compounds and their use as pharmaceuticals
SG163518A1 (en)	2010-08-30	Amido compounds and their use as pharmaceuticals
BRPI0510428A (pt)	2007-10-30	composições tópicas de metadona e processos para utilização das mesmas
BR0214343A (pt)	2004-09-14	Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
ID27503A (id)	2001-04-12	Tts yang mengandung antioksidan
SE0101387D0 (sv)	2001-04-20	Novel compounds
EA200970841A1 (ru)	2010-04-30	Фармацевтическое применение замещенных амидов
TW200637529A (en)	2006-11-01	Topical patch cooling preparation and methods for using the same
WO2008108286A1 (ja)	2008-09-12	経皮吸収医薬組成物、医薬組成物貯蔵ユニットおよびこれを利用する経皮吸収製剤
BR0308429A (pt)	2005-01-11	Aroilpiridinonas monocìclicas como agentes antiinflamatórios
SG161261A1 (en)	2010-05-27	Lactam compounds and their use as pharmaceuticals
WO2004037201A3 (en)	2004-10-21	Topical skin care composition
MX2010004613A (es)	2010-05-20	Composicion topica.
DE602005021770D1 (de)	2010-07-22	Indol-1-yl-essigsäurederivate
BRPI0620431A8 (pt)	2018-01-09	uso de um poliuretano formador de película, preparação farmacêutica líquida, aplicador e emplastro contendo a referida preparação farmacêutica
ATE345160T1 (de)	2006-12-15	Topisches produkt mit visuellem indikator
AU2003296692A1 (en)	2005-01-21	Lipidic protein-transfer systems and cosmetic/dermatological use thereof
PT1638582E (pt)	2009-05-28	Uso de ácido hialurónico para a preparação de composições para o tratamento de aftas recorrentes da cavidade bucal
TNSN07203A1 (en)	2008-11-21	Pharmaceutical compositions for the treatment of cellulite
TNSN04235A1 (en)	2007-03-12	Compositions for therapeutic use comprising a vitamin, a metal salt and insulin or a growth hormone
DE60127839D1 (de)	2007-05-24	Pflaster mit 4-biphenylessigsäure